Natasha Thorne

Natasha Thorne

Company: FDA

Job title: Team Lead


Dr. Thorne has been involved in regulating companion diagnostics to gene therapies since she first started at the FDA seven years ago. Prior to the FDA, Dr. Thorne worked at the National Institutes of Health, where she was involved in projects to support the preclinical development of therapies to treat rare or neglected diseases.


AAV Gene Therapy Specific Regulatory Guidelines for Companion Diagnostics 1:30 pm

Outlining the Study Risk Determination process of CDRH and CBER in evaluating a CDx application Key regulatory considerations for accelerating the development of a CDx alongside an AAV gene therapy product Comparing PMA and HDE submissions: comparing and contrasting the required elements of both, and guidance for selecting one study route over the otherRead more

day: Day 2 Track B PM

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.